Cargando…
IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression
BACKGROUND: Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug targets and therapeutic strategies. In neuroblastoma, chromosomal gains at chromosome 17q...
Autores principales: | Hagemann, Sven, Misiak, Danny, Bell, Jessica L., Fuchs, Tommy, Lederer, Marcell I., Bley, Nadine, Hämmerle, Monika, Ghazy, Ehab, Sippl, Wolfgang, Schulte, Johannes H., Hüttelmaier, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226260/ https://www.ncbi.nlm.nih.gov/pubmed/37246217 http://dx.doi.org/10.1186/s12943-023-01792-0 |
Ejemplares similares
-
The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021) -
IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors
por: Müller, Simon, et al.
Publicado: (2018) -
The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer
por: Müller, Simon, et al.
Publicado: (2020) -
IGF2BP1, a Conserved Regulator of RNA Turnover in Cancer
por: Glaß, Markus, et al.
Publicado: (2021) -
The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family
por: Busch, Bianca, et al.
Publicado: (2016)